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Summary Several milestones in the systemic treat-
ment of lung cancer have been reached. Combina-
tion chemotherapy of small cell lung cancer was the
first of these milestones. The establishment of pal-
liative chemotherapy in patients with advanced non-
small cell lung cancer and of adjuvant chemotherapy
in patients with completely resected non-small cell
lung cancer was another important milestone. Tar-
geted therapies with angiogenesis inhibitors, EGFR in-
hibitors, and ALK inhibitors also advanced treatment.
The clinical introduction of immune checkpoint in-
hibitors was the latest milestone.
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Introduction
Although a rare disease in 1900, lung cancer has be-
come the most common cancer worldwide because
of the smoking epidemic of the twentieth century. In
2012, 1.8 million patients were diagnosed with and
1.6 million patients died from this cancer [1]. While
lung cancer has been classified as small cell lung can-
cer (SCLC) and non-small cell lung cancer (NSCLC)
for many decades, the 2015 classification of lung
cancer mandates further subclassification by means
of immunohistochemical and molecular analyses in
routine clinical practice [2]. Patients with advanced
NSCLC, particularly those with adenocarcinomas, are
currently tested for the presence of epidermal growth
factor receptor (EGFR) mutations, ALK aberrations,
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and ROS1 aberrations in their tumors because these
molecular alterations have therapeutic consequences.
Additional molecular analyses are expected to enter
routine clinical practice in the near future.
Several therapeutic advances have occurred over
the years. Major milestones in the treatment of lung
cancer were combination chemotherapy for SCLC,
palliative chemotherapy for advanced NSCLC, adju-
vant chemotherapy in patients with completely re-
sected NSCLC, targeted therapies, and, most recently,
treatment with immune checkpoint inhibitors. The
present manuscript summarizes these therapeutic
milestones.
Combination chemotherapy for SCLC
SCLC is often widespread with clinically detectable
metastases in about two thirds of the patients at
the time of diagnosis. SCLC has been recognized
as a chemosensitive disease and the introduction of
combination chemotherapy in the second half of the
last century was unequivocally a milestone in the
treatment of lung cancer (see [3] for review). Pal-
liative combination chemotherapy increases median
survival times four- to five-fold compared with best
supportive care alone and relieves cancer-related
symptoms in the majority of symptomatic patients.
Combination chemotherapy was shown to be supe-
rior to single agents in terms of survival and quality
of life, thereby stressing the fact that tumor control
by chemotherapy clearly outweighs the toxicities as-
sociated with combination chemotherapy [3]. Further
therapeutic advances were the introduction of tho-
racic radiotherapy in patients with limited disease,
prophylactic brain irradiation in patients who have
responded to initial therapy, and topotecan as second-
line chemotherapy.
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Palliative chemotherapy of advanced NSCLC
The establishment of palliative chemotherapy in pa-
tients with advanced NSCLC, particularly in the first-
line setting, is considered as a therapeutic milestone.
A meta-analysis of randomized trials was published in
1994 and demonstrated a survival benefit from first-
line chemotherapy compared with best supportive
care alone [4]. This led to the widespread implemen-
tation of first-line chemotherapy as clinical standard
for patients with advanced NSCLC.
Further improvements were achieved by the third-
generation cytotoxic drugs, which were shown to be
superior and/or better tolerated than older drugs.
Currently, patients receive first-line chemotherapy
with up to six cycles of a platinum-based dou-
blet containing a third-generation cytotoxic drug
[5, 6]. Compared with best supportive care alone,
first-line chemotherapy increases median survival by
1.5 months and the 1-year survival rate by 9% and
also relieves cancer-related symptoms in about one
half of the symptomatic patients [5].
Cisplatin-based chemotherapy is slightly superior
to carboplatin-based chemotherapy [7]. Cisplatin-
based chemotherapy resulted in a higher response
rate compared with carboplatin-based chemotherapy
(30% vs. 24%) and carboplatin-based chemotherapy
was associated with an increase in mortality in pa-
tients treated with third-generation anticancer drugs
(HR = 1.11; 95% confidence interval = 1.01–1.21) and
also in patients with non-squamous NSCLC (HR =
1.12; 95% confidence interval = 1.01–1.23) [7]. In
clinical practice, cisplatin-based chemotherapy is
preferred in patients with good performance status
in the absence of clinically relevant comorbidities,
whereas carboplatin-based chemotherapy is used in
patients with reduced organ functions (kidney, heart)
and when ease of administration is of particular im-
portance. Elderly patients and patients with reduced
performance status also benefit from well-tolerated
chemotherapy protocols such as single agents or car-
boplatin-based doublets.
First-line chemotherapy is currently combined with
bevacizumab in selected patients with non-squamous
cell NSCLC or with necitumumab in patients with
EGFR-positive squamous cell NSCLC (see next sec-
tion). After the establishment of first-line chemother-
apy, maintenance therapy and second-line therapy
became standard treatment for selected patients with
advanced NSCLC [6].
Adjuvant chemotherapy in patients with resected
NSCLC
Approximately 25–30% of patients with NSCLC are di-
agnosed with localized disease and undergo surgery
with curative extent. Up to 70% of these patients, how-
ever, will relapse systemically because of the presence
of micro-metastases at the time of surgery. There-
fore, adjuvant chemotherapy was studied in order to
improve the outcome of patients with completely re-
sected NSCLC. The meta-analysis of early randomized
trials published in 1994 suggested a trend toward im-
proved survival for adjuvant chemotherapy [4]. This
potential survival benefit together with the availability
of better anticancer drugs and anti-emetics led to the
re-evaluation of adjuvant chemotherapy in random-
ized trials on large patient populations.
Three of these randomized trials demonstrated
a survival benefit for adjuvant cisplatin-based
chemotherapy in patients with completely resected
NSCLC [8–11]. The increase in the 5-year survival rates
ranged between 4 and 15% in these trials. The Lung
Adjuvant Cisplatin Evaluation (LACE) meta-analysis,
which was based on 4,584 patients from five cisplatin-
based chemotherapy trials (ALPI-EORTC, IALT, JBR10,
ANITA, Big Lung Trial), confirmed the survival benefit
with a hazard ratio of 0.89 (95% CI = 0.82–0.96; p =
0.004) for adjuvant chemotherapy which translates
into a survival benefit of 5.3% ± 1.6% at 5 years [12].
Disease-free survival was also prolonged by adjuvant
chemotherapy and the hazard ratio was 0.8 (95% CI =
0.78–0.9; p < 0.001). These findings led to the estab-
lishment of adjuvant cisplatin-based chemotherapy
as a standard for patients with completely resected
NSCLC stages II and III and for selected patients
with stage IB. Adjuvant chemotherapy consists of four
cycles of a cisplatin-based doublet. Based on the ev-
idence from clinical trials, cisplatin plus vinorelbine
can be considered as the preferred chemotherapy
protocol.
Strategies that have been studied to improve the
outcome of adjuvant chemotherapy include the char-
acterization of predictive biomarkers for patient selec-
tion, customized chemotherapy based on biomarkers,
targeted therapies, and immunotherapies. To date,
however, none of these strategies has been successful.
Targeted therapies
The establishment of targeted therapies in patients
with advanced NSCLC is another therapeutic mile-
stone. Targeted therapies have focused on inhibition
of angiogenesis, EGFR, or ALK.
While many angiogenesis inhibitors have been
studied, only few have entered clinical practice. Be-
vacizumab was the first angiogenesis inhibitor to
be approved in combination with platinum-based
chemotherapy in patients with advanced non-squa-
mous NSCLC. This approval was based on the results
of two phase 3 trials that demonstrated superior out-
come for chemotherapy plus bevacizumab compared
with chemotherapy alone in patients with advanced
non-squamous cell NSCLC [13, 14].
Nintedanib, a triple kinase inhibitor, and ramu-
cirumab, a monoclonal antibody against vascular
EGFR, have also been approved in the combina-
tion with second-line chemotherapy with docetaxel.
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Compared with docetaxel alone, nintedanib added
to docetaxel improved progression-free survival and,
in patients with adenocarcinomas, also overall sur-
vival [15]. This led to the approval of nintedanib
in combination with docetaxel for patients with ad-
vanced adenocarcinomas who have been pretreated
with chemotherapy. Ramucirumab increased survival
when added to docetaxel in patients with advanced
NSCLC and was also approved [16].
Blockade of the EGFR by monoclonal antibodies,
tyrosine kinase inhibitors, and other approaches has
also been studied to improve outcome in patients
with advanced NCSLC (for review, see [17]). Several
anti-EGFR monoclonal antibodies have been eval-
uated in clinical trials (for review, see [18]). First-
line chemotherapy combined with cetuximab im-
proved survival in patients with advanced NSCLC,
particularly in those with high EGFR expression in
their tumors [19, 20]. This benefit was confirmed
in a meta-analysis based on four randomized trials
[21]. Necitumumab added to first-line chemotherapy
with cisplatin plus gemcitabine increased survival of
patients with advanced squamous cell NSCLC [22].
Although the benefit with cetuximab was similar to
the one of necitumumab, only necitumumab has
been approved by the European Medicines Agency.
Tyrosine kinase inhibitors of the EGFR have initially
been studied in unselected patients with advanced
NSCLC. Excellent activity of these drugs was seen in
never-smokers, patients of South-East Asian ethnicity,
and patients with adenocarcinomas. In 2004, these
patients were found to harbor EGFR mutations in
their tumors [23–25]. Several studies then demon-
strated the superiority of tyrosine kinase inhibitors
over first-line chemotherapy in terms of progression-
free survival and quality of life in patients with ad-
vanced EGFR mutation-positive NSCLC (for review,
see [17]). A survival benefit has been demonstrated for
afatinib [26]. Thus patients with advanced EGFR mu-
tation-positive NSCLC receive EGFR tyrosine kinase
inhibitors as first-line therapy. At the time of disease
progression, patients are switched to chemother-
apy or, in the presence of the T790 M mutation, to
osimertinib [27, 28]. Patients with advanced ALK-
positive NSCLC are treated with crizotinib or other
ALK inhibitors [29–31].
Immune checkpoint inhibitors
The most recent milestone in the treatment of lung
cancer was the introduction of immune checkpoint
inhibitors into clinical practice in patients with ad-
vanced NSCLC. These drugs are directed against cy-
totoxic T lymphocyte-associated antigen 4 (CTLC4),
programmed death-1 (PD-1), and PD-1 ligands PD-
L1 and PD-L2. Drugs that have been studied in lung
cancer are ipilimumab, nivolumab, pembrolizumab,
atezolizumab, durvalumab, and avelumab.
Nivolumab and pembrolizumab have shown ef-
ficacy in phase 3 trials in patients with advanced
NSCLC who had been pretreated with chemotherapy
[32–34]. Nivolumab has shown a survival benefit com-
pared with docetaxel in advanced squamous NSCLC
and in adenocarcinomas [32, 33]. Pembrolizumab
showed superiority over docetaxel in patients with
PD-L1 expression on at least 1% of tumor cells [34].
The survival benefit was seen with both doses of
pembrolizumab (hazard ratios of 0.71 and 0.61 for
2mg/kg and 10mg/kg, respectively) and was more
pronounced in patients with PD-L1expression in 50%
or more of tumor cells. The anti-PD-L1 antibody ate-
zolizumab improved overall survival compared with
docetaxel in a randomized phase 2 trial, particularly
in patients with enriched PD-L1 expression on tumor
cells and tumor-infiltrating immune cells [35]. Side
effects of immune checkpoint inhibitors are immune-
related pneumonitis, colitis, hepatitis, nephritis, en-
docrinopathies, infusion-related events, and others
[31–35].
Immune checkpoint inhibitors have also been
studied in the first-line setting. Pembrolizumab
has demonstrated superior progression-free survival
and overall survival compared with platinum-based
chemotherapy in patients with PD-L1 expression in
at least 50% of the tumor cells [36]. By contrast,
nivolumab failed to improve outcome compared with
chemotherapy in patients with PD-L1 expression in
at least 5% of tumor cells [37].
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